<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are clonal disorders affecting hematopoietic progenitor cells (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Despite the relevance of clonal CD34+ cells in developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, only few studies analyze the phenotype of this cell population </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to evaluate phenotypic changes on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> that could reflect abnormalities in the differentiation process of stem cells </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We analyzed the expression of CD38 and HLA-DR on CD34+ cells by flow cytometry in 36 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, as well as in healthy donors (n = 12) and patients with other <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e>: non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, both in complete remission (CR) (n = 32); <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> in CR (n = 17); de novo <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) at diagnosis (n = 22) and in CR (n = 37); and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> secondary to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> at diagnosis (n = 19) </plain></SENT>
<SENT sid="4" pm="."><plain>Cases with available karyotype were grouped according to the International Prognostic Scoring System (IPSS) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Compared to <z:mpath ids='MPATH_458'>normal</z:mpath> BM, the fraction of immature <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>, characterized as CD34+bright, intermediate FSC/SSC, and CD38dim, was significantly increased in high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e>, but not in low risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, (P &lt; or = 0.001, P = 0.03, and P = 0.7) </plain></SENT>
<SENT sid="6" pm="."><plain>De novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> showed decreased immature <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>High numbers of immature <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> correlated with higher IPSS risk groups (P = 0.05) and showed significant impact on disease progression (P = 0.03) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Our study confirms that evaluation of CD38 expression pattern on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> is an easy and reproducible test that allows evaluating the immature subset of progenitor cells </plain></SENT>
<SENT sid="9" pm="."><plain>Increased immature <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> in high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> may reflect blocked differentiation of CD34+ cells in these diseases </plain></SENT>
</text></document>